Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 12, Issue 11, 2010, Pages 901-906

  Rubin, Richard R ^a   Peyrot, Mark ^a,b   Chen, Xiaojing ^c   Frias, Juan P ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

^c LifeScan Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLULISINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HUMAN; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 78649361211     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0075     Document Type: Article

References (18)

1. Weng JP, Li YB, Xu W, Shi LX, Zhang Q, Zhu DL, Hu Y, Zhou ZG, Yan X, Tian HM, Ran XW, Luo ZJ, Xian J, Yan L, Li FP, Zeng LY, Chen YM, Yang LY, Yan SJ, Liu J, Li M, Fu ZZ, Cheng H: Effect of intensive insulin therapy on B-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753-1760.
2. Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smede-gaard JS, Lauritzen T, Christiansen JS: Insulin and glucose profiles during subcutaneous insulin infusion compared with injection of long-acting insulin in type 2 diabetes. Diabet Med 2008;25:585-591.
3. Peyrot M, Rubin RR: Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire. Diabetes Care 2005;28:53-58.
4. Pickup JC, Renard E: Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-S145.
5. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I: Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med 2005;22:1037-1046.
6. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28: 1568-1573.
7. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603.
8. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research/Center for Devices and Radiological Health, 2006. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm071975.pdf (accessed September 14, 2009).
9. Marra G; DIAB. & TE.S Study Group: The DIAB. & TE.S Project: how patients perceive diabetes and diabetes therapy. Acta Biomed 2004;75:164-170.
10. Charpentier G, Fleury F, Dubroca I, Vaur L, Clerson P: Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005;31:189-195.
11. Edelman SV, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Chen XJ, Frias JP: Insulin pump therapyinpatients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther 2010;12:627-633.
12. Arbuckle RA, Humphrey L, Vardeva K, Arondekar B, Danten-Viala Msc M, Scott JA, Snoek FJ: Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)\a measure of symptom distress. Value Health 2009;12:1168-1175.
13. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-349.
14. Siegel JE, Weinstein MC, Russell LB, Gold MR: Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339-1341.
15. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41: 582-592.
16. Peyrot M, Rubin RR: How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference. Diabetes Care 2009;32:1411-1417.
17. Rubin RR, Peyrot M: Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. Diabetes Educ 2009;35:136-146.
18. Peyrot M, Rubin RR, Polonsky WH: Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther 2008;10:461-466.